By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cancer diagnostics firm Dako said today it is collaborating with Genentech on the regulatory submission in the US of two Dako tests as companion diagnostics for Genentech's investigational drug candidate for breast cancer.

The companies will partner on submitting Dako's HercepTest and Her2 FISH pharmDx to the US Food and Drug Administration as companion diagnostics for Genentech's pertuzumab as a treatment for patients with advanced HER2-positive breast cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.